This house believes that: MARI/TAD is better than sentinel node biopsy after PST for cN+ patients

Annemiek K. E. van Hemert, Frederieke H. van Duijnhoven, Marie-Jeanne T. F. D. Vrancken Peeters

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

The increasing use and effectiveness of primary systemic treatment (PST) enables tailored locoregional treatment. About one third of clinically node positive (cN+) breast cancer patients achieve pathologic complete response (pCR) of the axilla, with higher rates observed in Human Epidermal growth factor Receptor (HER)2-positive or triple negative (TN) breast cancer subtypes. Tailoring axillary treatment for patients with axillary pCR is necessary, as they are unlikely to benefit from axillary lymph node dissection (ALND), but may suffer complications and long-term morbidity such as lymphedema and impaired shoulder motion. By combining pre-PST and post-PST axillary staging techniques, ALND can be omitted in most cN + patients with pCR. Different post-PST staging techniques (MARI/TAD/SN) show low or ultra-low false negative rates for detection of residual disease. More importantly, trials using the MARI (Marking Axillary lymph nodes with Radioactive Iodine seeds) procedure or sentinel lymph node biopsy (SLNB) as axillary staging technique post-PST have already shown the safety of tailoring axillary treatment in patients with an excellent response. Tailored axillary treatment using the MARI procedure in stage I-III breast cancer resulted in 80% reduction of ALND and excellent five-year axillary recurrence free interval (aRFI) of 97%. Similar oncologic outcomes were seen for post-SLNB in stage I-II patients. The MARI technique requires only one invasive procedure pre-NST and a median of one node is removed post-PST, whereas for the SLNB and TAD techniques two to four nodes are removed. A disadvantage of the MARI technique is its use of radioactive iodine, which is subject to extensive regulations.
Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalBreast (Edinburgh, Scotland)
Volume71
DOIs
Publication statusPublished - 1 Oct 2023

Keywords

  • Breast cancer
  • Pathologic response
  • Primary systemic treatment
  • Tailored axillary treatment

Cite this